

# Utilization of the T2 Candida Panel for rapid Candida species detection in a large community hospital

Ali Hassoun, MD FACP FIDSA, Mohamed Abdulhaleem, MD, Jonathan Edwards, Pharm.D., BCPS-AQID, BCGP  
Huntsville Hospital - Huntsville, Alabama

Ali Hassoun, MD  
Alabama Infectious Diseases Center  
420 Lowell drive, suite 301  
Huntsville, AL 35801  
Ali\_hasoun@yahoo.com

## Background

- The CDC states that candidemia carries a 35% mortality rate and is the 4th leading hospital-acquired bloodstream infection
- Blood cultures take 2-6 days to result and fail to identify 40-50% of Candida infections
- The T2 Candida Panel is a diagnostic test which utilizes whole blood to provide rapid (3-5 hours) species-specific detection of fungal pathogens
- The test detects five species of Candida (*C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. krusei*, and *C. glabrata*)
- T2 is also designed to provide:
  - 96.4% sensitivity and 99.4% specificity
  - Accurate results even with current antimicrobial therapy
  - Limits detection as low as 1 CFU/mL
- Use of this panel could enable clinicians to initiate anti-fungal treatment quicker, deescalate therapy faster, and possibly decrease mortality


## Purpose

Continued evaluation of the utilization of T2 Candida Panel in a large community hospital

## Methods

- The T2 Candida Panel was restricted to two specialty departments, Infectious Disease (ID) and Oncology for use in specific patient populations
- Patient populations included:
  - Patients with febrile neutropenia without observed cause
  - Patients in the ICU for at least 72 hours, central venous line and unexplained fever, use of broad spectrum antibiotics, in addition to one of the following:
    - Acute pancreatitis, recent major surgery, total parenteral nutrition (TPN), neutropenia, renal/hepatic failure, corticosteroids
  - Patients with central venous line and unexplained fever, sepsis
- Endpoints were defined as medication use, patient characteristics and risk factors, T2 Candida Panel results, corresponding blood cultures, time to de-escalation, and duration of therapy (DOT)

## Results




## Evaluation of True Positives

	T2 (+)	T2 (-)
<b>Blood Culture (+)</b>	8	2
<b>Blood Culture (-)</b>	26	309

- Blood cultures identified 2 cases of fungal infections that were not detected by T2
- T2 identified 26 cases of fungal infections that were not detected by blood cultures
- T2 demonstrated a sensitivity similar to that found in published studies (94.4%)

## Average DOT of Micafungin (n=128)



## Discussion

- T2's sensitivity claim of 96.4% and its superiority claim over blood cultures received FDA approval in 2015
- Of the patients with a positive T2 result 8/34 (24%) had a positive corresponding blood culture
- 129/311 (41%) of patients were able to avoid antifungal therapy initiation based on negative T2 results
- Negative T2 tests resulted in discontinuation of antifungal therapy in 71/311 (23%) of patients
- Two negative T2 results had a corresponding positive blood culture
- Of 36 true positives, T2 detected 34 (94.9%) positive results
- 111/311 (36%) antifungal regimens were not discontinued despite a negative T2 result
- 83/345 (24%) T2 results did not have a concurrently drawn blood culture
- Average time to de-escalation was 40.8 hours
- Negative T2 results decreased average duration of therapy of micafungin by 2.1 days.

## Conclusions

- At our facility the T2 Candida Panel demonstrated greater sensitivity to Candida infection and produced results much quick when compared to blood cultures
- Despite the test's rapid nature and high sensitivity, time to de-escalation remains at 2 days suggesting variations in physicians' utilization of T2 test results

## References

1. Mylonakis, E, Clancy, C, Ostrosky-Zeichner, L, et al. (2015). T2 Magnetic Resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clinical infectious diseases*, 2015: ciu959.
2. Parkins, M, Sabuda, D, Elsayed, S, Laupland, K. (2007). Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. *Journal of antimicrobial chemotherapy*, 60(3), 613-618.
3. Gagne, J, Breitbart, R, Maio, V, et al. (2006). Costs associated with candidemia in a hospital setting. *P and T*, 31(10), 586.
4. Pfeiffer, C, Samsa, G, Schell, W, et al. (2011). Quantitation of Candida CFU in initial positive blood cultures. *Journal of clinical microbiology*, 49(8), 2879-2883.